Susan Hubbard - Exelixis President
| EXEL Stock | USD 22.87 0.05 0.22% |
President
Ms. Susan Hubbard serves as Executive Vice President Public Affairs and Investor Relations of the Company. As EVP of Public Affairs and Investor Relations, Susan Hubbard will oversee the company public affairs, advocacy and investor relations functions as a member of the company executive leadership team. Prior to joining Exelixis in a fulltime capacity, Ms. Hubbard served as an independent public affairs and investor relations consultant to the biopharmaceutical industry. From 2014 onward, she was instrumental in developing Exelixis communications strategy around the latestage clinical development, approval and commercial launch of CABOMETYX, as well as several major milestones for the company partnered programs. Previously, as one of the initial employees at Gilead Sciences she spent over two decades in roles of increasing responsibility, finishing her tenure as Vice President of Investor Relations. She received her undergraduate degree from University of California, Los Angeles. since 2016.
| Tenure | 8 years |
| Address | 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 |
| Phone | 650 837 7000 |
| Web | https://www.exelixis.com |
Exelixis Management Efficiency
The company has return on total asset (ROA) of 0.0355 % which means that it generated a profit of $0.0355 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0874 %, meaning that it created $0.0874 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Exelixis' Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.13 this year, although the value of Return On Equity will most likely fall to 0.10. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Intangibles To Total Assets will most likely fall to 0.02.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Gilmore ONeill | Sarepta Therapeutics | 53 | |
| Mark Gergen | Halozyme Therapeutics | 53 | |
| Dimitrios Chondros | Halozyme Therapeutics | 53 | |
| Greg Zante | Viking Therapeutics | N/A | |
| Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
| Edward Kaye | Sarepta Therapeutics | 66 | |
| Manmeet Soni | Alnylam Pharmaceuticals | 40 | |
| Peter Smith | Alnylam Pharmaceuticals | 58 | |
| Alan Eisenberg | Alnylam Pharmaceuticals | N/A | |
| Catherine StehmanBreen | Sarepta Therapeutics | 53 | |
| Richard Ranieri | Biomarin Pharmaceutical | 59 | |
| Catherine Kelleher | Viking Therapeutics | N/A | |
| Al Kildani | Halozyme Therapeutics | N/A | |
| Kelley Boucher | Alnylam Pharmaceuticals | N/A | |
| Daniel Spiegelman | Biomarin Pharmaceutical | 58 | |
| Harry Leonhardt | Halozyme Therapeutics | 61 | |
| Jeff Ajer | Biomarin Pharmaceutical | 55 | |
| Alison Armour | Halozyme Therapeutics | 53 | |
| Guriqbal Basi | Sarepta Therapeutics | 60 | |
| Masako Nakamura | Alnylam Pharmaceuticals | N/A | |
| Chids Mahadevan | BioXcel Therapeutics | 45 | |
Management Performance
| Return On Equity | 0.0874 | ||||
| Return On Asset | 0.0355 |
Exelixis Leadership Team
Elected by the shareholders, the Exelixis' board of directors comprises two types of representatives: Exelixis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exelixis. The board's role is to monitor Exelixis' management team and ensure that shareholders' interests are well served. Exelixis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exelixis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Garber, Independent Director | ||
| Susan Hubbard, Executive Vice President - Public Affairs and Investor Relations | ||
| Gregg Bernier, VP Marketing | ||
| George Scangos, Independent Director | ||
| Christopher Senner, CFO, Executive Vice President | ||
| Carl Feldbaum, Independent Director | ||
| Maria Freire, Director | ||
| Deborah Burke, CFO, Sr. VP and Controller | ||
| Anne MD, Senior Safety | ||
| Julie Smith, Director | ||
| Peter Lamb, Chief Scientific Officer and Executive VP of Discovery Research | ||
| Patrick Haley, Senior Vice President - Commercial | ||
| Vincent Marchesi, Independent Director | ||
| Laura Dillard, Executive Resources | ||
| Lance Willsey, Independent Director | ||
| Pamela Simonton, Executive Vice President | ||
| William MD, Senior Affairs | ||
| Michael Morrissey, CEO and President and Director | ||
| Patrick MBA, Executive Commercial | ||
| Dana Aftab, Executive Officer | ||
| Jeffrey Hessekiel, Executive Vice President General Counsel | ||
| George Poste, Independent Director | ||
| Jeffrey JD, General VP | ||
| Stelios Papadopoulos, Chairman and Member of Audit Committee | ||
| Jack Wyszomierski, Independent Director | ||
| Charles Cohen, Independent Director | ||
| MBA MBA, Ex Commercial | ||
| Gisela Schwab, Executive Vice President Chief Medical Officer |
Exelixis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exelixis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0874 | ||||
| Return On Asset | 0.0355 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 6.1 B | ||||
| Shares Outstanding | 303.19 M | ||||
| Shares Owned By Insiders | 2.33 % | ||||
| Shares Owned By Institutions | 88.10 % | ||||
| Number Of Shares Shorted | 6.83 M | ||||
| Price To Earning | 48.17 X |
Pair Trading with Exelixis
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exelixis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exelixis will appreciate offsetting losses from the drop in the long position's value.Moving against Exelixis Stock
| 0.42 | BIIB | Biogen Inc Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Exelixis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exelixis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exelixis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exelixis to buy it.
The correlation of Exelixis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exelixis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exelixis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exelixis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.Note that the Exelixis information on this page should be used as a complementary analysis to other Exelixis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Complementary Tools for Exelixis Stock analysis
When running Exelixis' price analysis, check to measure Exelixis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exelixis is operating at the current time. Most of Exelixis' value examination focuses on studying past and present price action to predict the probability of Exelixis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exelixis' price. Additionally, you may evaluate how the addition of Exelixis to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Exelixis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 0.65 | Revenue Per Share 5.753 | Quarterly Revenue Growth 0.131 | Return On Assets 0.0355 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.